Elevai Labs, Common Stock Today

ELAB Stock   0.02  0.0005  2.59%   

Performance

0 of 100

 
Weak
 
Strong
Very Weak

Odds Of Distress

Less than 25

 
High
 
Low
Low
Elevai Labs, is trading at 0.0188 as of the 13th of November 2024, a 2.59 percent decrease since the beginning of the trading day. The stock's open price was 0.0193. Elevai Labs, has about a 25 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Elevai Labs, Common are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 14th of September 2024 and ending today, the 13th of November 2024. Click here to learn more.
Business Domain
Health Care Equipment & Services
IPO Date
21st of November 2023
Category
Healthcare
Classification
Health Care
Elevai Labs, is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 20.8 M outstanding shares of which 9.42 M shares are currently shorted by private and institutional investors with about 1.33 trading days to cover. More on Elevai Labs, Common

Moving against Elevai Stock

  0.76BSX Boston Scientific CorpPairCorr
  0.75VMD Viemed HealthcarePairCorr
  0.65LNSR LENSAR IncPairCorr
  0.57DRIO DarioHealth CorpPairCorr
  0.55FIGS Figs IncPairCorr
  0.47MMSI Merit Medical SystemsPairCorr

Elevai Stock Highlights

President CoFounderJordan Plews
Thematic IdeaPharmaceutical Products (View all Themes)
Business ConcentrationHealth Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, Pharmaceutical Products, Health Care, Health Care Equipment & Supplies, Biotechnology, Healthcare (View all Sectors)
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.20.33
Way Down
Slightly volatile
Total Current Liabilities1.4 M1.3 M
Sufficiently Up
Slightly volatile
Total Assets5.4 M5.2 M
Sufficiently Up
Slightly volatile
Total Current Assets5.2 M4.9 M
Sufficiently Up
Slightly volatile
Elevai Labs, can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Elevai Labs,'s financial leverage. It provides some insight into what part of Elevai Labs,'s total assets is financed by creditors.
Liquidity
Elevai Labs, Common currently holds 210.49 K in liabilities. Note, when we think about Elevai Labs,'s use of debt, we should always consider it together with its cash and equity.

Change In Cash

2.28 Million
Elevai Labs, Common (ELAB) is traded on NASDAQ Exchange in USA. It is located in 120 Newport Center Drive, Newport Beach, CA, United States, 92660 and employs 18 people. Elevai Labs, is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.45 M. Elevai Labs, Common conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 20.8 M outstanding shares of which 9.42 M shares are currently shorted by private and institutional investors with about 1.33 trading days to cover. Elevai Labs, generates negative cash flow from operations
Check Elevai Labs, Probability Of Bankruptcy
Ownership Allocation
Elevai Labs, holds a total of 20.8 Million outstanding shares. Elevai Labs, Common retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Elevai Ownership Details

Elevai Labs, Historical Income Statement

At present, Elevai Labs,'s Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Selling And Marketing Expenses is expected to grow to about 693.3 K, whereas Depreciation And Amortization is forecasted to decline to about 11.1 K. View More Fundamentals

Elevai Stock Against Markets

Elevai Labs, Corporate Executives

Elected by the shareholders, the Elevai Labs,'s board of directors comprises two types of representatives: Elevai Labs, inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Elevai. The board's role is to monitor Elevai Labs,'s management team and ensure that shareholders' interests are well served. Elevai Labs,'s inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Elevai Labs,'s outside directors are responsible for providing unbiased perspectives on the board's policies.
FACS FACSChief CoFounderProfile
Graydon CFASecretary CFOProfile
When determining whether Elevai Labs, Common offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Elevai Labs,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Elevai Labs, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Elevai Labs, Common Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Elevai Labs, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Elevai Labs,. If investors know Elevai will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Elevai Labs, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.42)
Revenue Per Share
0.168
Quarterly Revenue Growth
0.913
Return On Assets
(0.89)
Return On Equity
(3.51)
The market value of Elevai Labs, Common is measured differently than its book value, which is the value of Elevai that is recorded on the company's balance sheet. Investors also form their own opinion of Elevai Labs,'s value that differs from its market value or its book value, called intrinsic value, which is Elevai Labs,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Elevai Labs,'s market value can be influenced by many factors that don't directly affect Elevai Labs,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Elevai Labs,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Elevai Labs, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Elevai Labs,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.